DDInter1376 DDInter1063
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a
Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol (levalbuterol).
Levosalbutamol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Beclomethasone dipropionate
Levosalbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Levosalbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Levosalbutamol {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Levosalbutamol may cause a minor interaction that can limit clinical effects when taken with Beclomethasone dipropionate
Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Levosalbutamol may lead to a major life threatening interaction when taken with Ribociclib